Should I Buy IMNM? IMNM 2026 Analysis

Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

26.650

1 Day change

1.95%

52 Week Range

27.230

Analysis Updated At

2026/01/29

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Immunome Inc (IMNM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including overwhelmingly positive Phase 3 trial results, significant analyst upgrades, and increasing hedge fund and insider buying. Despite weak financial performance in the latest quarter, the company's pipeline and market potential outweigh the negatives for long-term growth.

Technical Analysis

The technical indicators are bullish. The MACD is positive and contracting, the RSI is neutral at 62.62, and the moving averages show a bullish trend (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels (Pivot: 23.78, S1: 21.268) and has room to test resistance levels (R1: 26.292, R2: 27.843).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Positive Phase 3 trial results for varegacestat, with high statistical significance and potential to capture a $1B-$2B market.
Multiple analyst upgrades with increased price targets (ranging from $32 to $
and strong buy/outperform ratings.
Hedge funds and insiders are significantly increasing their buying activity.
High implied volatility (239.
and strong interest in call options suggest bullish sentiment.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with revenue dropping to 0 and EPS declining by 16.67%.
No recent news or congress trading data to provide additional support.

Financial Performance

In Q3 2025, the company reported a 100% YoY revenue drop, a net income improvement of 21.99% YoY (to -$57.46M), and a gross margin of 100%. However, EPS dropped by 16.67% to -0.65, reflecting ongoing financial challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are overwhelmingly positive on IMNM, with multiple firms raising price targets to $32-$40 and maintaining buy/outperform ratings. The positive Phase 3 trial results for varegacestat have bolstered confidence in its market potential, with analysts highlighting its potential to become a class leader in the desmoid tumor treatment market.

11 Analyst Rating

Wall Street analysts forecast IMNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 33.2 USD with a low forecast of 21 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 26.140

Low

Averages

33.2

High

Current: 26.140

Low

Averages

33.2

High

Guggenheim

Buy

upgrade

$25 -> $35

AI Analysis

2025-12-16

Reason

Guggenheim

Price Target

$25 -> $35

AI Analysis

2025-12-16

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Immunome to $35 from $25 and keeps a Buy rating on the shares after the company reported positive top-line Phase 3 trial results for varegacestat. The firm believes approval likelihood is high and that varegacestat is well-positioned to capture the majority share in the a potential $1B-$2B DT market in the U.S.

Evercore ISI

NULL

Outperform

upgrade

$18 -> $40

2025-12-16

Reason

Evercore ISI

Price Target

$18 -> $40

2025-12-16

upgrade

NULL

Outperform

Reason

Evercore ISI raised the firm's price target on Immunome to $40 from $18 and keeps an Outperform rating on the shares. The "overwhelmingly positive" results from the RINGSIDE trial bolstered confidence in varegacestat's potential as a leading treatment for desmoid tumors, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNM

Unlock Now

IMNM Should I Buy

IMNM Should I Buy

Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch